Cargando…

PD-L1/PD-1 blockage enhanced the cytotoxicity of natural killer cell on the non-small cell lung cancer (NSCLC) by granzyme B secretion

OBJECTIVE: To explore the role of PD-L1/PD-1 blockage in the cytotoxicity of natural killer cell in NSCLC. METHODS: Two NSCLC cell lines, Calu-1 and H460, were tested for susceptibility to the cytolytic activity of freshly isolated healthy donor NK cells by a non-radioactive cellular cytotoxicity as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qiao, Duan-Rui, Cheng, Jun-Ya, Yan, Wei-Qun, Li, Hai-Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293349/ https://www.ncbi.nlm.nih.gov/pubmed/36856921 http://dx.doi.org/10.1007/s12094-023-03120-w

Ejemplares similares

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
por: Wang, Xueping, et al.
Publicado: (2020)

Rac1/ROCK-driven membrane dynamics promote natural killer cell cytotoxicity via granzyme-induced necroptosis
por: Zhu, Yanting, et al.
Publicado: (2021)

Tumor Suppression by PD-1/PD-L1 Interaction Blockage in Mice Model
por: Salehi, Shima, et al.
Publicado: (2023)

PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells
por: Guo, Yanan, et al.
Publicado: (2016)

Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy
por: Bai, Rilan, et al.
Publicado: (2022)

PD-1-positive Natural Killer Cells have a weaker antitumor function than that of PD-1-negative Natural Killer Cells in Lung Cancer
por: Niu, Chao, et al.
Publicado: (2020)

Dinutuximab Synergistically Enhances the Cytotoxicity of Natural Killer Cells to Retinoblastoma Through the Perforin-Granzyme B Pathway
por: Wang, Huixue, et al.
Publicado: (2020)

Radiotherapy combined with PD‐1/PD‐L1 inhibitors in NSCLC brain metastases treatment: The mechanisms, advances, opportunities, and challenges
por: Chen, Zi‐Ying, et al.
Publicado: (2022)

Tislelizumab uniquely binds to the CC′ loop of PD‐1 with slow‐dissociated rate and complete PD‐L1 blockage
por: Hong, Yuan, et al.
Publicado: (2021)

Granzyme B for predicting the durable clinical benefit of anti-PD-1/PD-L1 immunotherapy in patients with non-small cell lung cancer
por: Chung, Jae Heun, et al.
Publicado: (2022)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
por: Niu, Mengke, et al.
Publicado: (2021)

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
por: Janning, Melanie, et al.
Publicado: (2019)

PD-1, PD-L1 and PD-L2 Gene Expression on T-Cells and Natural Killer Cells Declines in Conjunction with a Reduction in PD-1 Protein during the Intensive Phase of Tuberculosis Treatment
por: Hassan, Syeda S., et al.
Publicado: (2015)

Noncytotoxic functions of killer cell granzymes in viral infections
por: de Jong, Lisanne C., et al.
Publicado: (2021)

Human intestinal and circulating invariant natural killer T cells are cytotoxic against colorectal cancer cells via the perforin–granzyme pathway
por: Díaz‐Basabe, Angélica, et al.
Publicado: (2021)

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression
por: Masuda, Ken, et al.
Publicado: (2020)

YAP regulates PD-L1 expression in human NSCLC cells
por: Miao, Jinbai, et al.
Publicado: (2017)

Supramolecular Photothermal Nanomedicine Mediated Distant Tumor Inhibition via PD-1 and TIM-3 Blockage
por: Huang, Tong-Yi, et al.
Publicado: (2020)

Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells
por: Lian, Shu, et al.
Publicado: (2019)

G6PD functions as a metabolic checkpoint to regulate granzyme B expression in tumor-specific cytotoxic T lymphocytes
por: Lu, Chunwan, et al.
Publicado: (2022)

Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
por: Zhang, Jie, et al.
Publicado: (2015)

The PD-1/B7-H1 Pathway Modulates the Natural Killer Cells versus Mouse Glioma Stem Cells
por: Huang, Bo Yuan, et al.
Publicado: (2015)

PD-1(+) IFN-γ(+) subset of CD8(+) T cell in circulation predicts response to anti–PD-1 therapy in NSCLC
por: Chen, Wenxiu, et al.
Publicado: (2023)

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
por: Schmidt, Lars Henning, et al.
Publicado: (2015)

The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer
por: Yajuk, Olga, et al.
Publicado: (2021)

PD-1 blockade enhances cytokine-induced killer cell-mediated cytotoxicity in B-cell non-Hodgkin lymphoma cell lines
por: Li, Yutao, et al.
Publicado: (2021)

PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance
por: Zhang, Yan, et al.
Publicado: (2017)

Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells
por: Zhao, Yunlong, et al.
Publicado: (2018)

Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model
por: Liu, Wai Nam, et al.
Publicado: (2022)

Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1
por: Makowska, Anna, et al.
Publicado: (2020)

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
por: Kowanetz, Marcin, et al.
Publicado: (2018)

Leptin regulates Granzyme-A, PD-1 and CTLA-4 expression in T cell to control visceral leishmaniasis in BALB/c Mice
por: Dayakar, Alti, et al.
Publicado: (2017)

PD-1 Impairs CD8(+) T Cell Granzyme B Production in Aged Mice during Acute Viral Respiratory Infection
por: Parks, Olivia B., et al.
Publicado: (2023)

Immunity-Related Gene Signature Identifies Subtypes Benefitting From Adjuvant Chemotherapy or Potentially Responding to PD1/PD-L1 Blockage in Pancreatic Cancer
por: Qian, Hao, et al.
Publicado: (2021)

The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy
por: Quatrini, Linda, et al.
Publicado: (2020)

IDO1 Inhibition Reduces Immune Cell Exclusion Through Inducing Cell Migration While PD-1 Blockage Increases IL-6 and -8 Secretion From T Cells in Head and Neck Cancer
por: Sieviläinen, Meri, et al.
Publicado: (2022)

Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression
por: Lin, Ziying, et al.
Publicado: (2019)

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
por: Bie, Fenglong, et al.
Publicado: (2022)

Inflammatory and autoimmune predictive markers of response to anti-PD-1/PD-L1 therapy in NSCLC and melanoma
por: Musaelyan, Aram A., et al.
Publicado: (2022)

PD-1(T) TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
por: Hummelink, Karlijn, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u3e1stma8hrm43ul963lqv1j0r